Bayer provides innovative solutions
Bayer provides innovative solutions
Germany’s Bayer last week in partnership with Ho Chi Minh City’s Cardiology Association organised a science symposium themed as Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: Present and Future.
The one-day high-profile event held on August 1, on which Bayer Group also celebrated its 150th anniversary, attracted more than 200 healthcare professionals who are cardiologists and neurologists working in hospitals of Ho Chi Minh City and neighbouring provinces.
The symposium focused on the risk of stroke in patients with non-valvular atrial fibrillation, the causes of the disease, its burden on society, and, most importantly, preventative treatments available around the world. The discussion highlighted the importance of preventing strokes in patients with non-valvular atrial fibrillation.
Atrial fibrillation is the most common sustained cardiac rhythm disorder. Major cardiovascular organisations in the world such as American College of Cardiology, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee have announced that there are more than one third of patients hospitalised due to heart rhythm disturbances with 4.5 million patients with atrial fibrillation in Europe.
In Vietnam, according to a survey conducted by the National Heart Institute in conjunction with the World Health Organization showed that the number of patients with atrial fibrillation made up 0.3 per cent of the general population. Almost half of stroke sufferers due to atrial fibrillation are at risk of death while the remainder faced the risk of disability.
“Bayer is working closely with health care practitioners to introduce innovative drugs that will further improve the health of the nation. Strokes can be devastating to both patient and caregiver, and prevention should be a key priority,” said Manoj Saxena, country head of Bayer Health Care Pharmaceuticals in Vietnam.
vir
